Jefferies Group Analysts Give Evolent Health (EVH) a $22.00 Price Target

Evolent Health (NYSE:EVH) has been assigned a $22.00 target price by analysts at Jefferies Group in a report released on Tuesday. The firm presently has a “buy” rating on the technology company’s stock. Jefferies Group’s price target would indicate a potential upside of 61.17% from the stock’s previous close.

A number of other analysts have also recently issued reports on EVH. Citigroup began coverage on Evolent Health in a research note on Thursday, January 4th. They set a “buy” rating for the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $30.00 price target on shares of Evolent Health in a research report on Sunday, December 3rd. Leerink Swann set a $25.00 price objective on Evolent Health and gave the company a “buy” rating in a report on Saturday, November 18th. Goldman Sachs Group downgraded Evolent Health from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, November 7th. Finally, SunTrust Banks reissued a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $27.40.

Shares of Evolent Health (NYSE:EVH) traded down $0.05 during trading hours on Tuesday, reaching $13.65. The company’s stock had a trading volume of 318,986 shares, compared to its average volume of 929,132. The company has a market cap of $1,040.00 and a PE ratio of -11.93. Evolent Health has a 12-month low of $10.30 and a 12-month high of $27.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 3.34.

Several hedge funds and other institutional investors have recently modified their holdings of EVH. ETF Managers Group LLC acquired a new stake in Evolent Health in the second quarter valued at about $102,000. BNP Paribas Arbitrage SA boosted its stake in Evolent Health by 815.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock valued at $120,000 after buying an additional 4,232 shares in the last quarter. US Bancorp DE boosted its stake in Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after buying an additional 19 shares in the last quarter. Point72 Asia Hong Kong Ltd acquired a new stake in Evolent Health in the first quarter valued at about $126,000. Finally, Bank of Montreal Can boosted its stake in Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock valued at $138,000 after buying an additional 6,077 shares in the last quarter. Institutional investors own 95.44% of the company’s stock.

WARNING: “Jefferies Group Analysts Give Evolent Health (EVH) a $22.00 Price Target” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/13/jefferies-group-analysts-give-evolent-health-evh-a-22-00-price-target.html.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply